Supplementary Figure 1. Flow diagram of patient recruitment and selection for analysis
Supplementary Figure 2. Clarithromycin resistance and successful *H. pylori* eradication therapy.

Percentage of patients carrying A2142G, A2142C, or A2143G 23S-rRNA gene mutation among patients with successful or unsuccessful *H. pylori* eradication therapy (determined by monoclonal antigen stool test after 8 weeks of treatment) is shown. Analysis of the data obtained for 24 subjects was performed by $X^2$ test.